Sprint Bioscience (SPRINT) Q2 2025 earnings summary

Executive summary

• Completed a rights issue in Q2 2025, subscribed to 74% including guarantees, strengthening the shareholder base with new long-term investors.

• VRK1 cancer program returned after Day One Biopharmaceuticals ended the partnership; strategic reprioritizations and staff reductions followed.

• Initiated a research collaboration with EDDC in Singapore to expand the MASH program into inflammatory diseases.

• Published positive DCPS program results in the journal Leukemia, validating DCPS as a target for AML treatment.

Financial highlights

• Q2 2025 net revenue: 13.9 MSEK (16.7 MSEK Q2 2024); H1 2025 net revenue: 28.0 MSEK (34.6 MSEK H1 2024).

• Q2 2025 operating result: -6.8 MSEK (-5.6 MSEK Q2 2024); H1 2025 operating result: -11.8 MSEK (-9.4 MSEK H1 2024).

• Q2 2025 net result after tax: -7.4 MSEK (-5.8 MSEK Q2 2024); H1 2025 net result: -13.0 MSEK (-8.9 MSEK H1 2024).

• Q2 2025 EPS: -0.08 SEK (-0.08 SEK Q2 2024); H1 2025 EPS: -0.16 SEK (-0.13 SEK H1 2024).

• Cash flow from operations H1 2025: -18.4 MSEK (-12.9 MSEK H1 2024); cash at period end: 24.7 MSEK (36.0 MSEK 2024).

Outlook and guidance

• No formal forecast provided; management expresses confidence in the updated portfolio and ongoing partnership discussions.